Prioritizing vaccine introduction to China’s National Immunization Program: a multi-criteria decision analysis
This study provides a transparent, comprehensive, and quantifiable vaccine value framework to aid decision-making for introducing new vaccines into China's NIP. According to the MCDA results, HPV should be considered the top vaccine candidate for the NIP.
Authors
- Jianming Guo (ORCID: https://orcid.org/0000-0002-4343-8622)
- Tingting Chen (ORCID: https://orcid.org/0000-0003-4467-0244)
- Maobai Liu (ORCID: https://orcid.org/0000-0003-1155-5741)
- Siping Dong (ORCID: https://orcid.org/0000-0003-4661-7228)
- Bin Zheng (ORCID: https://orcid.org/0000-0002-1768-7609)
- Shuyan Guo
Institutions
- Fujian Medical University (CN)
- Wuhan University (CN)
- National Institute of Hospital Administration (CN)
- Union Hospital (CN)
Publication Details
- Journal
- BMC Public Health
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12889-024-21013-7
- Citations
- 2
- Primary Topic
- Vaccine Coverage and Hesitancy
- Type
- article
- Field-Weighted Citation Impact
- 1.06
Funders
- National Key Research and Development Program of China